Expression and clinical value of EIF3CL in serous ovarian cancer

Expression and clinical value of EIF3CL in serous ovarian cancer

Objectives This study aimed to explore the expression of eukaryotic translation initiation factor 3 subunit C-like in serous ovarian cancer samples (both paraffin-embedded and fresh samples) and evaluate its clinical value in patients with serous ovarian cancer. Methods Twenty-five fresh serous ovar...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tingting Li, Longyang Liu, Qudi Qiao, Zhongqiu Lin, Jianhuan Yuan, Zhaoyang Zeng, Jilong Yao
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-05-01
Series:	Journal of International Medical Research
Online Access:	https://doi.org/10.1177/03000605251340320
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Retracted: MYH10 Combines with MYH9 to Recruit USP45 by Deubiquitinating Snail and Promotes Serous Ovarian Cancer Carcinogenesis, Progression, and Cisplatin Resistance
by: Longyang Liu, et al.
Published: (2023-05-01)

Case Report: An ovarian epithelial-type serous adenocarcinoma of the testis was treated using systemic chemotherapy with bevacizumab, the treatment strategy used for ovarian serous carcinoma
by: Rui-Zhi Liu, et al.
Published: (2025-03-01)

Risk Factors for Recurrence in Serous Borderline Ovarian Tumors and Early-Stage Low-Grade Serous Ovarian Carcinoma
by: Jingjing Zhang, et al.
Published: (2025-04-01)

eIF4E Overexpression Is Associated with Poor Prognoses of Ovarian Cancer
by: Jun Zheng, et al.
Published: (2020-01-01)

New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer
by: Chuying Huo, et al.
Published: (2024-12-01)

Expression of selected epithelial–mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers
by: Pawel Sadlecki, et al.
Published: (2018-06-01)

IL-6R expression is an independent prognostic factor in high-grade serous ovarian cancer
by: Alexis M. Maagdenberg, et al.
Published: (2025-07-01)

Unveiling the Diagnostic Significance of Calprotectin in Serous Ovarian Carcinoma
by: Alkis Matsas, et al.
Published: (2025-07-01)

Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Expression and Its Correlation with Prognosis and Growth of Serous Ovarian Cancer: Correlation of DYRK3 with Ovarian Cancer Survival
by: Jia Sun, et al.
Published: (2024-01-01)

A Rare Case of Ovarian Serous Borderline Tumor with Brain Metastasis
by: Sonia Veran-Taguibao, et al.
Published: (2019-01-01)

Serous ovarian carcinoma. Cytological and immunocytochemical and molecular genetic diagnostics
by: O. G. Grigoruk, et al.
Published: (2016-09-01)

Serous borderline ovarian tumors (clinical features, morphology, treatment)
by: I. Yu. Davydova, et al.
Published: (2014-07-01)

Ovarian serous borderline tumors: specific characteristics of ultrasound images
by: M. A. Chekalova, et al.
Published: (2020-11-01)

Serous Ovarian Carcinoma Recurring as Malignant Mixed Mullerian Tumor
by: Demir Hale, et al.
Published: (2015-01-01)

Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker
by: Jianjun Wang, et al.
Published: (2017-06-01)

GATA3 and Aging Raise the Susceptibility of Metastasis to High-Grade Serous Ovarian Carcinoma
by: Mohnad Abdalla, et al.
Published: (2025-04-01)

LPCAT3 regulates the proliferation and metastasis of serous ovarian cancer by modulating arachidonic acid
by: Fang Wen, et al.
Published: (2025-02-01)

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.
by: Stefan Bentink, et al.
Published: (2012-01-01)

The Quantitative Indices of ERCC1 Expression in Serous Ovarian Cancer Tissue and the Efficacy of First-Line Platinum-Based Chemotherapy
by: T. A. Bogush, et al.
Published: (2020-05-01)

Integrative Analysis of Gene Expression and Promoter Methylation to Differentiate High-Grade Serous Ovarian Cancer from Benign Tumors
by: Ieva Vaicekauskaitė, et al.
Published: (2025-02-01)

RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer
by: Kyle C. Strickland, et al.
Published: (2025-08-01)

IMMUNOHISTROCHEMISTRY AND FLOW CYTOMETRIC CHARACTERISTICS OF INTRATUMORAL LYMPHOCYTES IN OVARIAN SEROUS ADENOCARCINOMA
by: E. V. Zuyeva, et al.
Published: (2014-09-01)

Metastatic Ovarian Serous Adenocarcinoma Clinically Presenting as Inflammatory Breast Cancer
by: Lingling Xian, et al.
Published: (2024-01-01)

Isolated Axillary Lymph Node Metastasis from Serous Ovarian Cancer
by: Hemant Goyal, et al.
Published: (2012-01-01)

Ovarian Fibroma with Serous Cystadenoma—An Unusual Combination: A Case Report
by: P. S. Jayalakshmy, et al.
Published: (2012-01-01)

Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
by: Samar Elorbany, et al.
Published: (2024-11-01)

Ovarian stimulation with letrozole in nulliparous young women with relapsing early-stage serous borderline ovarian tumors
by: Valeria Lombardi Fäh, et al.
Published: (2024-12-01)

High CD36 expression in the tumor microenvironmental vasculature correlates with unfavorable overall survival in high grade serous ovarian cancer
by: Christina T. Grech, et al.
Published: (2025-06-01)

Ovatodiolide triggers ferroptosis in high-grade serous ovarian cancer through HMOX1 upregulation
by: Yew-Min Tzeng, et al.
Published: (2025-09-01)

Ovarian serous carcinoma: A retrospective study of clinicopathological findings and postchemotherapy changes
by: Navatha Vangala, et al.
Published: (2020-01-01)

NMR-based serum metabolomics in patients with low-differentiated serous ovarian cancer
by: Mateusz M. Klimek, et al.
Published: (2025-06-01)

Extracellular vesicles display distinct glycosignatures in high-grade serous ovarian carcinoma
by: Kristina Mae Bienes, et al.
Published: (2025-01-01)

Translation directed by hepatitis A virus IRES in the absence of active eIF4F complex and eIF2.
by: Natalia Redondo, et al.
Published: (2012-01-01)

Habitat-based radiomics for preoperative differentiation between early-stage serous borderline ovarian tumors and malignant ovarian tumors
by: Xinping Yu, et al.
Published: (2025-05-01)

Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium.
by: Ernest K Amankwah, et al.
Published: (2011-01-01)

Association of a common variant of gene with increased risk of serous epithelial ovarian cancer
by: Li Ma, et al.
Published: (2017-02-01)

Functional study of laminin subunit α5 in high-grade serous ovarian cancer
by: Wang Tianli, et al.
Published: (2025-07-01)

Stem Cell-Associated Signatures Help to Predict Diagnosis and Prognosis in Ovarian Serous Cystadenocarcinoma
by: Li Li, et al.
Published: (2023-01-01)

The silent spread: exploring diverse metastatic pathways in high-grade serous ovarian cancer
by: Mengqi Deng, et al.
Published: (2025-03-01)

Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers.
by: Jonathan Beesley, et al.
Published: (2011-01-01)